Non invasive markers using for the assessment of fibrosis in hepatitis C;Utilisation des marqueurs non invasifs de fibrose dans la prise en charge de l'hépatite C

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 8-9 C3, 2007, Pages

  Zarski, Jean Pierre ^a   Bedossa, Pierre ^b   Bronowicki, Jean Pierre ^c   Doffoel, Michel ^d   Poynard, Thierry ^e  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b BEAUJON HOSPITAL   (France)

^c CHU NANCY BRABOIS   (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE SEVERITY; ELASTOGRAPHY; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; SEROLOGY;

EID: 35948930674     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(07)92561-0     Document Type: Article

References (29)

1. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France:results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000;32:477-81.
2. The French Metavir Cooperative Study Group. Intraobserver and inter-observer variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
3. Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-André JP, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005;41:257-64.
4. Regev A, Berho M, Jeffers IJ, Milikowski C, Molina EG, Pyrsopoulos NT et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-8.
5. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis:the smaller the sample, the milder the disease. J Hepatol 2003;39:239-44.
6. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
7. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-75.
8. Halfon P, Bourlière M, Deydier R, Botta-Fridlund D, Renou C, Tran A, et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006;101:547-55.
9. Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, et al. Prospective comparison of six non invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007;46:775-82.
10. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, et al. Validation of the Fibro Test biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003;49:450-4.
11. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004;3:8.
12. Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002;1:3.
13. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004;50:1344-55.
14. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373-81.
15. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26.
16. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple non-invasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-25.
17. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36 986-92.
18. Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, et al. Evaluation of a panel of non invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935-42.
19. Adams LA, Bulsara M, Rossi E, Deboer B, Speers D, George J, et al. Hepascore:an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-73.
20. Rosenberg WMC, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-13.
21. Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004;39:1239-47.
22. Poynard T, Halfon P, Castéra L, Ratziu V, Imbert-Bismut F, Naveau S, et al. Méta-analyse du Fibrotest (FT) pour le diagnostic de fibrose dans les 4 maladies du foie les plus fréquentes. Gastroenterol Clin Biol 2006;30:CA16, 1057.
23. Calès P, Halfon P, Leroy V, Rousselet MC, Bourlière M, de Muret A, et al. Méta-analyse des scores sanguins de fibrose hépatique au cours des hépatites chroniques C. Gastroenterol Clin Biol 2006;30:CA19:1058.
24. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54.
25. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography. Fibrotest, APRI and liver biopsy for the assessement of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50.
26. Foucher J, Chanteloup E, Vergniol J, Castéra L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastrography (FibroScan):a prospective study. Gut 2006;55:403-8.
27. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hep 2002;9:128-33.
28. HAS Méthode non invasive d'évaluation de la fibrose/cirrhose hépatique décembre 2006, http:///www.has-sante.fr
29. Castéra L. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines? J Hepatol 2007;46:528-30.